Evidence map›Paper›PMID 38758004›Full record

ArticleAntimicrobial agents and chemotherapy2024

Phenotypic amikacin resistance may not indicate poor response to amikacin in

L M Minuk, S K Brode, M Mehrabi, M K Sharma, M Stobart, H Soualhine, T K Marras

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

L M MinukDivision of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0009-0006-6165-6056
S K BrodeDivision of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
M MehrabiDivision of Respirology, Department of Medicine, Toronto Western Hospital, Toronto, Ontario, Canada.
M K SharmaNational Reference Centre for Mycobacteriology, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.
M StobartDepartment of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada.
H SoualhineNational Reference Centre for Mycobacteriology, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.ORCID 0000-0002-5526-6741
T K MarrasDivision of Respirology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-6986-3651

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When using amikacin to treat

Indexed as

AmikacinAnti-Bacterial AgentsMicrobial Sensitivity TestsMycobacterium avium ComplexMycobacterium avium-intracellulare InfectionAgedDrug Resistance, BacterialFemaleHumansLung DiseasesMaleMiddle AgedMutationPhenotypeRetrospective StudiesAmikacinAnti-Bacterial Agentsamikacinantimicrobial resistancemycobacterial infection (pulmonary)Mycobacterium avium

Identifiers

PMID38758004
PMCPMC11620508

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.